ProSomnus Sleep Technologies, a pioneer in Smart Sleep Medicine and the leading non-CPAP therapy for Obstructive Sleep Apnea (OSA), announced a strategic investment from Catalio Capital Management, L.P. to accelerate the global expansion of its technology-enabled sleep health platform.
Catalio has committed up to $38 million to support the development of next-generation remote patient monitoring and proprietary sleep diagnostic devices, fund comparative clinical studies, and scale the infrastructure needed to meet rising demand for patient-preferred OSA therapies.
ProSomnus provides FDA-cleared, patented, non-invasive oral devices integrated with remote patient monitoring and data-driven diagnostics, offering superior adherence and validated outcomes. Devices are covered by commercial insurance, Medicare, and TRICARE, which together represent over 200 million lives globally.
Catalio Capital Management is a New York-based healthcare investment firm with offices in London and Washington, D.C., focused on the full lifecycle of innovative healthcare investing and partnering with world-renowned scientist-entrepreneurs.
KEY QUOTES:
“Catalio’s investment affirms our mission to address the global public health burden of obstructive sleep apnea with precision, data‑driven medical solutions that create meaningful value loops for patients, clinicians, and payers. Demand for effective, economical, and patient‑preferred therapies continues to build. This partnership enables ProSomnus to expand access to care while advancing and scientifically validating our next generation sensor‑enabled medical devices. We appreciate Catalio’s partnership and look forward to accelerating the worldwide adoption of Smart Sleep Medicine.”
Len Liptak, CEO, ProSomnus Sleep Technologies
“This $38 million commitment provides the strategic financial framework to scale our core infrastructure while maintaining a relentless focus on the patient. By directing capital into advanced remote monitoring and rigorous clinical validation, we are ensuring our growth is measured not just by market share, but by demonstrable patient outcomes. These investments allow us to lower the cost of care, increase treatment efficacy, and create a sustainable model for both our shareholders and the patients we serve.”
Jason Orchard, CFO, ProSomnus Sleep Technologies
“Sleep medicine is rapidly shifting toward data-driven, patient-preferred therapies. ProSomnus is leading that transition with connected oral devices that are clinically effective and consistently used by patients. We’re excited to strategically support the global launch of their next-generation product and broader vision for a scalable connected sleep medicine platform.”
Dr. Nicholas von Guionneau, Board Observer, Catalio Capital Management
